Patrick Alan Hagen, MD
Medical Oncology, Hematology, Hematology & Oncology, Internal Medicine
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888
Appointments (New Patients Welcome)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888Services & Specialties
Areas of Specialization
- Hematology
- Hematology & Oncology
- Internal Medicine
- Medical Oncology
Clinical Interests
Conditions Treated
- cancer chemotherapy
- bone marrow aspiration
- stem cell harvest
- cellular therapy
- cellular therapy - allogeneic
- cellular therapy - autologous
- cellular therapy - chimeric antigen T-cell (CAR-T)
- bone marrow biopsy
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood
, IL 60153
Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center at Melrose Park
715 W N Ave
Melrose Park
, IL 60160
About
My work at Loyola University incorporates both pre-clinical and clinical research as well as direct patient care. I am passionate about working with patients to find the best treatment choice tailored to each individual. My focus is primarily on plasma cell disorders including monoclonal gammopathy of unknown significance (MGUS), smoldering myeloma, multiple myeloma, plasma cell leukemia, amyloidosis (both systemic and ATTR), light chain deposition disease, and POEMS disease. However, I see patients for all malignant hematology conditions including acute and chronic leukemia, non-hodgkin and hodgkins lymphoma, a well as MDS and aplastic anemia. In particular, I focus on the role of high dose chemotherapy and autologous or allogeneic transplant as well as cellular therapy (CAR-T) in the care of patients. Further, it is my goal that every patient be offered and ideally treated on a clinical trial in order to improve patient outcomes. I am involved in translational as well as early and late phase clinical trial development.
Finally, I truly enjoy working with referring physicians and am passionate about finding the best treatment for mutual patients either here at Loyola or ideally locally if possible. I am always available to discuss the best care options for patients regardless of intent to refer to us for a second opinion or clinical trial opportunities.
Academic Title
Associate Professor
Leadership Title
Associate Director of the Cardinal Bernardin Cancer Center Clinical Trials Office
Interim Director of the Transplantation and Cellular Therapy Program
Ages Seen
Additional Resources
Education & Certifications
Education
Education:
St George's University School of Medicine
(2011)
Residency:
University of Minnesota Medical School
(2014)
Fellowship:
Loyola University Stritch School of Medicine
(2017)
Board Certifications
Hematology, Hematology, American Board of Internal Medicine Subspecialty (2020)
Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (2017)
Internal Medicine, Internal Medicine, American Board of (2014)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- Autologous stem cell transplantation in AL amyloidosis: Muddy waters. Hagen, P.; D'Souza, A.; Blood reviews
- Caspase 8 deletion causes infection/inflammation-induced bone marrow failure and MDS-like disease in mice. Liu, S.; Joshi, K.; Zhang, L.; Li, W.; Mack, R.; Runde, A.; Hagen, P. A.; Barton, K.; Breslin, P.; Ji, H. L.; Kini, A. R.; Wang, Z.; Zhang, J.; Cell death & disease
- Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma. Hagen, P.; Norton, J.; Tsai, S.; Campo, L.; Lee, M.; Gomez, K.; Stiff, P.; British journal of haematology
- Distinct roles of hematopoietic cytokines in the regulation of leukemia stem cells in murine MLL-AF9 leukemia. Li, Y.; Seet, C. S.; Mack, R.; Joshi, K.; Runde, A. P.; Hagen, P. A.; Barton, K.; Breslin, P.; Kini, A.; Ji, H. L.; Zhang, J.; Stem cell reports
- Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation. Shaw, R.; Haque, A. R.; Luu, T.; O'Connor, T. E.; Hamidi, A.; Fitzsimons, J.; Varda, B.; Kwon, D.; Whitcomb, C.; Gregorowicz, A.; Roloff, G. W.; Bemiss, B. C.; Kallwitz, E. R.; Hagen, P. A.; Berg, S.; Frontiers in oncology
- Exploring health behaviors and the feasibility of a lifestyle intervention for patients with multiple myeloma. Hodge, A.; Sheean, P.; O'Connor, P.; Tyler, K.; Kerschner, A.; Williams, A.; Jensik, K.; Visotcky, A.; D'Souza, A.; Hari, P.; Dhakal, B.; Chhabra, S.; Flynn, K. E.; Hagen, P.; Stolley, M.; Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
- Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia. Dadrass, F.; Esmail, F.; Regmi, A.; Mudaliar, K.; Mirza, K. M.; Kini, A. R.; Kim, W.; Hagen, P.; Hossain, N. M.; Clinical case reports
- The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. Sellin, M.; Berg, S.; Hagen, P.; Zhang, J.; Translational oncology
- High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Hagen, P.; Zhang, J.; Barton, K.; Blood cancer journal
- Increasing genomic discovery in newly diagnosed multiple myeloma: defining disease biology and its correlation to risk. Hagen, P.; Sellin, M.; Berg, S.; Zhang, J.; Annals of hematology
- COVID-19 thromboembolism incidence, risk factors, and anticoagulation practices from a Chicago metropolitan US population. Berg, S.; Kim, S. H.; Wozniak, A.; Odetola, O.; Arain, S.; Aleem, A.; Coggan, J.; Dave, A.; Elliott, E.; Guerrettaz, R.; Dalal, H.; Lee, R.; Kodali, A.; Moore, P.; Patel, S.; Rajakumar, P.; Qin, S.; Delgado Ramos, G.; Schwartz, C.; Esmail, F.; Feltman Frank, R.; Murchie, E.; Pax, L.; Yun, N.; Zhang, Y.; Barton, K.; Hagen, P.; Hossain, N.; Larson, M. L.; Mai, H.; Nand, S.; Phelan, K.; Venugopal, P.; Stiff, P.; Saraf, S.; American journal of hematology
- Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Pasvolsky, O.; Yeshurun, M.; Fraser, R.; Estrada-Merly, N.; Rozovski, U.; Shargian-Alon, L.; Assal, A.; Banerjee, R.; Bumma, N.; Gale, R. P.; Hagen, P.; Holmberg, L.; Hossain, N. M.; Lazarus, H. M.; Lee, C.; Mian, H.; Miller, K. C.; Nathan, S.; Nagler, A.; Nishihori, T.; Parrondo, R. D.; Patel, S.; Schroeder, M. A.; Usmani, S. Z.; Wang, T.; Wirk, B.; Kumar, S.; Shah, N.; Qazilbash, M. H.; D'Souza, A.; Bone marrow transplantation
- Time to Complete Response after Defibrotide Initiation in Hepatic Veno-Occlusive Disease: Is Less Actually More? Hagen, P.; Hossain, N.; Transplantation and cellular therapy
- Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen. Hagen, P.; D'Souza, A.; Hari, P.; Davila, O.; Zhang, M. J.; Vesole, D. H.; Smith, S. E.; Rodriguez, T. E.; Stiff, P. J.; Leukemia & lymphoma
- When Monoclonal Gammopathy is of Renal Significance: A Case Study of Crystalglobulinemia From Chicago Multiple Myeloma Rounds. Gilmore, B. A.; Rodby, R. A.; Cimbaluk, D.; Venugopal, P.; Patel, P.; Barton, K.; Hagen, P.; Rodriguez, T.; Sumoza, L.; Bishop, M. R.; Dhakal, B.; Hari, P.; Paner, A.; Clinical lymphoma, myeloma & leukemia
- The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma. Hagen, P. A.; Stiff, P.; Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
- Low mean post-transplantation tacrolimus levels in weeks 2-3 correlate with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from related and unrelated donors. Hagen, P. A.; Adams, W.; Smith, S.; Tsai, S.; Stiff, P.; Bone marrow transplantation